**National Institute for Health and Care Excellence**

### Surveillance Review of CG140 Palliative care for adults: strong opioids for pain relief

### Stakeholder Comments Form

|  |  |
| --- | --- |
| **Please enter the name of your registered stakeholder organisation below.**  **NICE is unable to accept comments from non-registered organisations. If you wish your comments to be considered please register via the** [**NICE website**](http://www.nice.org.uk/get-involved/stakeholder-registration) **or contact the** [**registered stakeholder organisation**](https://www.nice.org.uk/guidance/cg140/history) **that most closely represents your interests and pass your comments to them.** | |
| Stakeholder Organisation: |  |
| Name of commentator: |  |

***Please note an overview of the process for reviewing NICE published clinical guidelines can be found*** [**here**](https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/developing-NICE-guidelines-the-manual.pdf)

**Contents:**

* Comments on proposal not to update the guideline – page 2
* Comments on the proposal to put the guideline on the static list – page 2
* Comments on the proposal to remove research recommendations from the NICE version of the guideline and the NICE research recommendations database – page 3
* Comments on equality issues or areas excluded from the guideline scope – page 3

**Proposal not to update the guideline**

In order to guide your comments, please refer to the following questions:

1. Do you agree that the guidance should not be updated?
2. Do you agree with our proposal to put the guideline on the static list?
3. Do you agree with our proposal to remove the listed research recommendations from the NICE version of the guideline and the NICE research recommendation database?

If a stakeholder wishes to draw our attention to published literature, please supply the full reference. Please add extra rows as needed

| **1. Do you agree the guideline should not be updated?** | **Comments**  **If you disagree, please explain why** |
| --- | --- |
| Agree / Disagree (please delete as appropriate) | Comments on proposal not to update the guideline |

| **2. Do you agree with the proposal to put the guideline on the static list?** | **Comments**  **If you disagree, please explain why** |
| --- | --- |
| Agree / Disagree (please delete as appropriate) | Comments on proposal to put the guideline on the static list |

| **2. Do you agree with the proposal to remove these research recommendations from the NICE version and research database?** | | **Comments**    **If you disagree, please explain why** |
| --- | --- | --- |
| Is prophylactic prescription of anti-emetic treatment or the availability of anti-emetic treatment at the patient’s home more effective in reducing nausea than the availability of prescription on request for patients starting strong opioids for the treatment of pain in advanced or progressive disease? The outcomes of interest are nausea, time to control of nausea, patient acceptability of treatment, concordance and use of healthcare resources. | Agree / Disagree (please delete as appropriate) | Comments on proposal to remove the research recommendation |
| Is early switching of opioid, on development of side effects, more effective at reducing central side effects than persisting with current opioid and dose reduction in patients starting strong opioids? The outcomes of interest are time to clinically effective pain control with acceptable side effects. |  |  |

# Do you have any comments on equality issues or areas excluded from the original scope?

|  |
| --- |
|  |

**Please email this form to:** [**surveillance@nice.org.uk**](mailto:surveillance@nice.org.uk)

**Closing date: 5pm 26 May 2016**

**PLEASE NOTE:** The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion or the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.